Cas:2238-07-5 diglycidyl ether manufacturer & supplier

We serve Chemical Name:diglycidyl ether CAS:2238-07-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

diglycidyl ether

Chemical Name:diglycidyl ether
CAS.NO:2238-07-5
Synonyms:1,2:6,7-diepoxy-4-oxaheptane;Ether,diglycidyl;Diepoxy propyl ether;EINECS 218-802-6;oxiranylmethyl ether;monoglycidyl ether;DIGLYCIDYL ETHER;Diallyl Ether Dioxide;bisglycidyl ether;Glycidyl ether
Molecular Formula:C6H10O3
Molecular Weight:130.14200
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:260 °C
Density:1.12
Index of Refraction:1.446-1.448
PSA:34.29000
Exact Mass:130.06300
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:2922
Packing Group:III


Contact us for information like 1,2:6,7-diepoxy-4-oxaheptane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Glycidyl ether physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,bisglycidyl ether Use and application,Diallyl Ether Dioxide technical grade,usp/ep/jp grade.


Related News: The United Kingdom, for instance, is now warning against all but essential travel to mainland China, and is advising against all travel to Hubei province, where the outbreak was first reported. diglycidyl ether manufacturer ��No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise,�� said Kristen Devito, Global Director, Catalent Clinical Supply Services. diglycidyl ether supplier Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. diglycidyl ether vendor In the current trial, a total of 196 patients were randomly chosen to receive either the vaccine or a placebo. diglycidyl ether factory In the current trial, a total of 196 patients were randomly chosen to receive either the vaccine or a placebo.